Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Respir Med ; 210: 107176, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36871866

RESUMO

Background Long-term respiratory effects can occur after COVID-19 pneumonia (CP). The COVID Lung Ultrasound Study (COVIDLUS) aimed to investigate the utility of serial lung ultrasound (LUS) to track functional and physiological recovery after hospitalisation in patients with CP. Methods Between April 2021 and April 2022, 21 patients were recruited at discharge (D0). LUS was performed on D0, day 41 (D41) and day 83 (D83). CT Thorax was performed on D83. Lymphocyte count, Ferritin, Lactate Dehydrogenase, Troponin, CRP, and D-dimers were measured at D0, D41 and D83. 6 minute walking test (6MWT) was performed on D83 and quality of life questionnaires and spirometry completed on D41 and D83. Results 19 subjects completed the study (10 males [52%]; mean age: 52 years [range:37-74]). 1 patient died. LUS scores were significantly higher at D0, compared to D41 and D83 (Mean score:10.9 [D0]/2.8 [D41]/1.5 [D83]; p < 0.0001). LUS scores correlated poorly with CT at D83 (Pearson r2 = 0.28). Mean lymphocyte counts were lower at D0 but increased at D41 and D83. Mean serum Ferritin was significantly lower at D41 and D83, as compared to D0. The mean 6MWT distance was 385 m (130-540 m). Quality of life measures did not differ at D41 and D83. Lung function increased between D41 and D83 with mean increase in FEV1 and FVC of 160 ml and 190 ml respectively. Conclusion LUS can monitor the early recovery of lung interstitial changes from CP. The utility of LUS to predict development of subsequent lung fibrosis post-COVID deserves further study.


Assuntos
COVID-19 , Fibrose Pulmonar , Humanos , Masculino , Pessoa de Meia-Idade , COVID-19/complicações , COVID-19/diagnóstico por imagem , Pulmão/diagnóstico por imagem , Qualidade de Vida , Ultrassonografia/métodos , Feminino , Adulto , Idoso
2.
BMJ Case Rep ; 13(12)2020 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-33384344

RESUMO

Hafnia alvei is a rare, poorly understood commensal bacterium which has, on occasion, been shown to infect humans. We present two cases. The first patient presented with a 1-week history of dyspnoea, pleurisy and a productive cough, and the second with a prodrome of fatigue and night sweats. The former had a history of severe chronic obstructive pulmonary disease and the latter had a history of Crohn's disease. Both patients had underlying comorbidities and immunosuppression, but differed in presentation, radiological findings and recovery. This case series aims to remind readers of the broad differential of pathogens that can lead to disease in the immunocompromised and that one should not dismiss atypical cultured bacteria as commensal too hastily.


Assuntos
Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Ciprofloxacina/uso terapêutico , Claritromicina/uso terapêutico , Infecções por Enterobacteriaceae/diagnóstico , Infecções por Enterobacteriaceae/tratamento farmacológico , Hafnia alvei/isolamento & purificação , Pneumonia Bacteriana/diagnóstico , Pneumonia Bacteriana/tratamento farmacológico , Adulto , Idoso , Antibacterianos/uso terapêutico , Comorbidade , Doença de Crohn/complicações , Infecções por Enterobacteriaceae/epidemiologia , Feminino , Humanos , Hospedeiro Imunocomprometido , Masculino , Pneumonia Bacteriana/epidemiologia , Doença Pulmonar Obstrutiva Crônica/complicações , Doenças Raras/epidemiologia , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA